High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery
| Autor: | Johannes Schilling, Martin Janz, Ulrich Keller, Dirk Schürmann, Jörg Hofmann, Stephan Mathas, Benedikt Weissbrich, Matthias Obenaus, Stefan Schwartz, Thomas Schneider, Bernhard Gebauer, Oliver Schildgen, Ann-Christin von Brünneck |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Cancer Research Lung infection Pulmonary disease 03 medical and health sciences 0302 clinical medicine medicine In patient 030212 general & internal medicine Pathogen biology business.industry Human bocavirus Original Research Letters medicine.disease biology.organism_classification respiratory tract diseases 030228 respiratory system Atypical pneumonia Immunology Medicine business Glucocorticoid medicine.drug |
| Zdroj: | ERJ Open Research, Vol 7, Iss 2 (2021) ERJ Open Research article-version (VoR) Version of Record |
| ISSN: | 2312-0541 |
| Popis: | Human bocavirus (HBoV), which belongs to Parvoviridae, is a well-defined pathogen of respiratory infections, particularly in young children [1]. In contrast, the frequency of HBoV infections in adults with respiratory symptoms is virtually unknown and its causative role in respiratory failure is debated [1, 2]. Furthermore, the observation that dexamethasone is beneficial in COVID-19 patients with respiratory failure requiring respiratory support has gained great interest [3]. However, whether glucocorticoid treatment is useful in other severe viral respiratory diseases is a matter of controversy [4]. Human bocavirus (HBoV) has to be considered a life-threatening pathogen in adults with atypical pneumonia. Pulsed high-dose glucocorticoid treatment may be beneficial in patients suffering from severe pulmonary disease caused by HBoV or other viruses. https://bit.ly/3epiMyO |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|